Simvastatin switch savings
Express Scripts member plans have saved $230 million on cholesterol-fighting drugs through increased generic utilization since January 2006, the pharmacy benefit manager reports April 26. The PBM aggressively promoted therapeutic switching from Pfizer's Lipitor (atorvastatin) to Merck's Zocor (simvastatin) prior to the introduction of generic simvastatin (1"The Pink Sheet" Oct. 24, 2005, p. 19). With the launch of generic simvastatin and generic pravastatin (Bristol-Myers Squibb's Pravachol) in 2006, "use of generic cholesterol-fighting drugs has increased from eight percent to 44 percent," Express Scripts says...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.